Transcript 18.55-19.10 Findings and recommendations of the Good Governance for Medicines Programme evaluation pptx, 67kb

First Evaluation of Good Governance
for Medicines Programme
2004-2012
Brief Summary of Findings
Purpose of the Evaluation
• To analyse experiences and lessons learnt
after 8 years of implementation
Principal Findings (1)
In Phase II and III countries:
Improved medicines procurement
Revised pharmaceutical laws and regulations
Increased transparency in registration and
licensing
Improved management of conflict of interest
More public information on medicines policy
and governance
Principal Findings (2)
Increased awareness about impact of weak
governance, including unethical behaviour, on
country capacity to achieve universal access
Increased commitment to create and sustain
transparency in key stages of the medicines
chain
Increased international awareness
Acknowledged value of 3 phase methodology
Value for money
Observation
In some countries GGM process is strongly
country owned and driven. Others remain
dependent on WHO support.
This has implications for WHO skills, capacities
and resources.
Lessons learnt (1)
Increased vulnerability due to:
• Inability to control medicines promotion
• Weak policy base and lack of operational procedures
on medicines registration
• Lack of formal criteria to guide selection of members
of key committees e.g. medicines selection
• Lack of public access to information about medicines
legislation, regulations and written procedures
Lessons learnt (2)
Factors that promote good implementation:
• High national priority to tackling corruption including
tangible support at highest political levels
• Intersectoral mechanisms for improving good
governance, including ministry of finance
• Dedicated GGM management group comprising
senior stakeholder representatives
• WHO support specific to country context,
benchmarking progress and sharing lessons
Lessons learnt (3)
• GGM is about strenghthening systems and
reducing vulnerability through increased
transparency and promoting ethical conduct.
• The GGM methodology:
 Engages stakeholders
 Increases awareness
 Stimulates dialogue
 Identifies problems
Towards next phase of GGM (1)
• GGM experience should inform future WHO
work on strengthening transparency and
institutional integrity
• It should become an integral component of
WHO action to promote universal coverage
(2) Implications
WHO must:
• Complete unfinished work, especially to
develop impact indicators for monitoring and
evaluation
• Establish strong and consistent staff and
budgetary support across 3 levels of the
organization
(3) Dialogue with partners
• Evaluation showed partner interest in GGM
but wanted to know more e.g. through regular
updates
• Widen remit to include private sector
• Opportunities to use GGM tools more widely
e.g. in the wider health sector, for risk
assessment
• More work needed to measure effectiveness